ApopLogic Pharmaceuticals

ApopLogic Pharmaceuticals is a biotechnology company focused on developing novel pro-apoptotic therapies for the treatment of cancer. The company's lead candidate, AL-101, is a recombinant version of the human TNF-related apoptosis-inducing ligand (TRAIL) designed to selectively trigger programmed cell death in cancer cells while sparing healthy tissue. ApopLogic's research targets the extrinsic apoptosis pathway, specifically focusing on death receptors DR4 and DR5. The company aims to overcome the limitations of previous TRAIL-based therapies through improved protein engineering and combination strategies. Founded as a spin-out from the University of Colorado, the company was part of the Fitzsimons Innovation Community.